Peripheral T cell lymphomas (PTCL) are rare in children and adolescents, and data about outcome and treatment results are scarce. The present study is a joint, international, retrospective analysis of 143 reported cases of non-anaplastic PTCL in patients <19 years of age, with a focus on treatment and outcome features. One hundred forty-three patients, between 0.3 and 18.7 years old, diagnosed between 2000 and 2015 were included in the study. PTCL not otherwise specified was the largest subgroup, followed by extranodal NK/T cell lymphoma, hepatosplenic T cell lymphoma (HS TCL), and subcutaneous panniculitis-like T cell lymphoma (SP TCL). Probability of overall survival (pOS) at 5 years for the whole group was 0.56 ± 0.05, and probability of event-free survival was (pEFS) 0.45 ± 0.05. Patients with SP TCL had a good outcome with 5-year pOS of 0.78 ± 0.1 while patients with HS TCL were reported with 5-year pOS of only 0.13 ± 0.12. Twenty-five percent of the patients were reported to have a pre-existing condition, and this group had a dismal outcome with 5-year pOS of 0.29 ± 0.09. The distribution of non-anaplastic PTCL subtypes in pediatric and adolescent patients differs from what is reported in adult patients. Overall outcome depends on the subtype with some doing better than others. Pre-existing conditions are frequent and associated with poor outcomes. There is a clear need for subtype-based treatment recommendations for children and adolescents with PTCL.

Belarusian Research Center for Pediatric Oncology Hematology and Immunology Minsk Belarus

Bone Marrow Transplantation and Pediatric Hematology and Oncology Wroclaw Medical University Wroclaw Poland

Clinic of Paediatrics Haemathology and Oncology Medical University of Gdansk Gdansk Poland

Department of Paediatric Haematology and Oncology Great North Children's Hospital Newcastle Hospitals NHS Foundation Trust Newcastle upon Tyne UK

Department of Pediatric Hematology and Oncology The Queen Silvia's Hospital for Children Rondvägen 10 41685 Göteborg Sweden

Department of Pediatric Oncology and Hematology University Children's Hospital Banska Bystrica Slovakia

Department of Pediatric Oncology Hôpital des Enfants Toulouse France

Department of Pediatrics and Adolescent Medicine Li Ka Shing Faculty of Medicine Queen Mary Hospital The University of Hong Kong Pokfulam Hong Kong

Department of Pediatrics Division of Hematology and Oncology Hospital for Sick Children Toronto ON Canada

Department of Pediatrics Sapporo Hokuyu Hospital Sapporo Japan

Division of Pediatric Hematology Oncology and Stem Cell Transplantation University Medical Center Aachen Germany

Pediatric Hematology and Oncology Addbrooke's Hospital Cambridge University Hospitals Foundation Trust Cambridge UK

Pediatric Hematology and Oncology Charles University and University Hospital Motol Prague Czech Republic

Pediatric Hematology and Oncology Federal Center for Pediatric Hematology Oncology and Immunology Moscow Russia

Pediatric Hematology and Oncology Semmelweis University Budapest Hungary

Pediatric Hematology and Oncology St Anna Children's Hospital Medical University of Vienna Vienna Austria

Pediatric Hematology and Oncology University Hospitals Leuven Leuven Belgium

Pediatric Hematology and Oncology University of Padova Padova Italy

Pediatric Oncology and Hematology University Hospital Brno Czech Republic

Princess Maxima Center for Pediatric Oncology Utrecht The Netherlands

Citace poskytuje Crossref.org

Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

Non-Hodgkin lymphoma and pre-existing conditions: spectrum, clinical characteristics and outcome in 213 children and adolescents